A large quantity of studies have testified to the aberrant expression of AGAP2-AS1 in human malignancies, including glioma, colorectal, lung, ovarian, prostate, breast, cholangiocarcinoma, bladder, colon and pancreatic cancers. Here, AGAP2 is linked to familial pancreatic carcinoma.